26 February 2025 Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks Download Presentation Webcast Workbook
26 February 2025 Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting Download Presentation Webcast Workbook
13 January 2025 Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer Download Presentation Webcast Workbook
16 August 2024 Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3 Download Presentation Webcast Workbook
23 May 2024 SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE Download Presentation Webcast Workbook
13 May 2024 Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 Download Presentation Webcast Workbook
19 April 2024 SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION Download Presentation Webcast Workbook
21 March 2024 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival Download Presentation Webcast Workbook
7 March 2024 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial Download Presentation Webcast Workbook
31 January 2024 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial Download Presentation Webcast Workbook
5 January 2024 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 Download Presentation Webcast Workbook
21 November 2023 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months Download Presentation Webcast Workbook